SCHEDULE: Wellington Management Discloses 5.5% Stake in Revolution Medicines

Wellington Management Group LLP and its affiliates reported a 5.5% beneficial ownership stake in Revolution Medicines, Inc. as of June 30, 2025.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, filed an Amendment No. 6 to Schedule 13G.
• The filing reports beneficial ownership of common Stock in Revolution Medicines, Inc. (CUSIP: 76155X100).
• As of June 30, 2025, the aggregate amount beneficially owned by the reporting persons is 10,259,738 shares.
• This represents 5.5% of the class of common stock of Revolution Medicines, Inc.
• The reporting persons hold shared voting power over 9,091,423 shares and shared dispositive power over 10,259,738 shares.
• No reporting person holds sole voting or sole dispositive power over any shares.
• The securities are owned of record by clients of the Wellington Investment Advisers, who retain the right to receive dividends or proceeds from the sale of such securities.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, which can be a signal of institutional confidence or interest in Revolution Medicines, Inc.

Key Dates

Keywords

Revolution Medicines, RVMD, Wellington Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Pharmaceutical, Biotechnology